



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

by carbapenemase-producing *Enterobacteriaceae* or multiresistant *Acinetobacter baumannii*. Except for ESBL *Klebsiella pneumoniae*, which is more frequent on admission in patients with SCI, we have not found other patient characteristics related to a certain MDRO detected on admission or as an aetiology of infection.

As for factors related to the presence of MDROs, we agree with other studies that low functional level is a risk factor for presenting MDROs at admission, unlike the length of time with the injury or other factors described in the literature (age, sex).<sup>4–6</sup> MDRO infections are more frequent in patients with SCI, due to a higher incidence of urological infections,<sup>8</sup> and patients with MDROs at admission (61% with MDROs vs. 39% without MDROs at admission;  $p < 0.001$  chi-square test). Although 6.6% of patients had MDRO infections during hospitalisation, it is noteworthy that in 39% of them MDROs were not detected on admission, which reveals the transmission and/or acquisition of new MDROs during the hospital stay, a circumstance already described in our centre for ESBL *Enterobacteriaceae*.<sup>9</sup>

In patients with MDRO infection, the length of hospital stay in the IG was significantly longer, in the same way as has been described in nosocomial infections in general.<sup>10</sup>

In conclusion, the notable presence of patients with MDROs on admission, especially in those most dependent, and its possible consequences (transmission, infection, hospital stay), make control measures in neurorehabilitation centres essential, especially screening on admission.

## Acknowledgements

To Hatice Kumru, Ana Alonso, Mariona Secanell and Eloy Opisso for their invaluable contribution to the completion of this study.

## References

1. Red Nacional de Vigilancia Epidemiológica (RENAVE). Disponible en: [https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Paginas/Microorganismos-multirresistentes-](https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Paginas/Microorganismos-multirresistentes-.aspx)

2. .aspx Protocolo de vigilancia y control de microorganismos multirresistentes o de especial relevancia clínico-epidemiológica (Protocolo-MMR); 2016.
3. Mackintosh S. Functional independence measure. Aust J Physiother. 2009;55:65. [http://dx.doi.org/10.1016/s0004-9514\(09\)70066-2](http://dx.doi.org/10.1016/s0004-9514(09)70066-2).
4. Oteo J, Bou G, Chaves F, Oliver A. Microbiological methods for surveillance of carrier status of multiresistant bacteria. Enferm Infecc Microbiol Clin. 2017;35:667–75. <http://dx.doi.org/10.1016/j.eimc.2015.12.013>.
5. Bilavsky E, Lerman Y, Rabinovich A, Salomon J, Lawrence C, Rossini A, et al. Carriage of methicillin-resistant *Staphylococcus aureus* on admission to European rehabilitation centres—a prospective study. Clin Microbiol Infect. 2012;18:E164–9. <http://dx.doi.org/10.1111/j.1469-0691.2012.03851.x>.
6. Bilavsky E, Temkin E, Lerman Y, Rabinovich A, Salomon J, Lawrence C, et al. Risk factors for colonization with extended-spectrum beta-lactamase-producing *Enterobacteriaceae* on admission to rehabilitation centres. Clin Microbiol Infect. 2014;20:0804–10. <http://dx.doi.org/10.1111/1469-0691.12633>.
7. Rollnik JD, Bertram M, Bucka C, Hartwich M, Jöbges M, Ketter G, et al. Outcome of neurological early rehabilitation patients carrying multi-drug resistant bacteria: results from a German multi-center study. BMC Neurol. 2017;17:53. <http://dx.doi.org/10.1186/s12883-017-0833-2>.
8. Sociedad Española de medicina Preventiva Salud Pública e Higiene. Available from: <https://epine.es/api/documento-publico/2019%20EPINE%20Informe%20España%2027112019.pdf/reports-esp>, 2019.
9. Garcia-Arguello LY, O'Horo JC, Farrell A, Blakney R, Sohail MR, Evans CT, et al. Infections in the spinal cord-injured population: a systematic review. Spinal Cord. 2017;55:526–34. <http://dx.doi.org/10.1038/sc.2016.173>.
10. Adler A, Baraniak A, Izdebski R, Fiett J, Salvia A, Samso JV, et al. A multinational study of colonization with extended spectrum  $\beta$ -lactamase-producing *Enterobacteriaceae* in healthcare personnel and family members of carrier patients hospitalized in rehabilitation centres. Clin Microbiol Infect. 2014;20:0516–23. <http://dx.doi.org/10.1111/1469-0691.12560>.
11. Mylotte JM, Graham R, Kahler L, Young BL, Goodnough S. Impact of nosocomial infection on length of stay and functional improvement among patients admitted to an acute rehabilitation unit. Infect Control Hosp Epidemiol. 2001;22:83–7. <http://dx.doi.org/10.1086/501868>.

Margarita Vallès<sup>a,\*</sup>, Conxita Romero<sup>a</sup>, Laura Cervera<sup>a,b</sup>, Sergiu Albu<sup>a</sup>

<sup>a</sup> Institut Guttmann, Badalona, Barcelona, Spain

<sup>b</sup> Hospital Universitari Dr Peset, Valencia, Spain

\* Corresponding author.

E-mail address: [mvalles@guttmann.com](mailto:mvalles@guttmann.com) (M. Vallès).

<https://doi.org/10.1016/j.eimc.2022.04.010>

2529-993X/ © 2021 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Published by Elsevier España, S.L.U. All rights reserved.

## Multisystem inflammatory syndrome in adults associated to SARS-CoV-2<sup>☆,☆☆</sup>



### Síndrome inflamatorio multisistémico del adulto asociado a SARS-CoV-2


Paediatric multisystem inflammatory syndrome is a condition described in 2020 as a result of the COVID-19 pandemic and whose pathogenesis is not completely clear.<sup>1</sup> Cases have also been described in adults, in whom it is much more infrequent; the largest series published to date is of 51 cases.<sup>2</sup>

We describe a case of multisystem inflammatory syndrome in adults (MIS-A) and its histopathology.

<sup>☆</sup> This case was awarded first prize in the COVID SEIMC-Gilead clinical case contest at the XXIV Congress of the Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica, held online from 5 to 11 June 2021.

<sup>☆☆</sup> Please cite this article as: Llenas-García J, Paredes-Martínez ML, Boils-Arroyo PL, Pérez-Gómez IM. Síndrome inflamatorio multisistémico del adulto asociado a SARS-CoV-2. Enferm Infecc Microbiol Clin. 2022;40:407–408.

The patient was a 31-year-old woman, with a history of lymphocytic meningitis of probable viral origin in 2010 and pyelonephritis in 2018. She was diagnosed in January 2021 with mild COVID-19 (positive antigen test), progressed favourably and was discharged two weeks later. Four weeks later she began with fever, headache, vomiting, mild diarrhoea and very intense pain in the right iliac fossa (RIF) for which she went to the emergency department. She was admitted on the fourth day after the onset of symptoms. At that time, she was febrile (38.5 °C), with blood pressure of 95/70 mmHg, heart rate of 96 bpm and baseline oxygen saturation of 98%. Of note were her mucocutaneous pallor, RIF pain on palpation and mild neck stiffness. Laboratory tests revealed thrombocytopenia, anaemia, lymphopenia, and elevated ESR, D-dimer, ferritin and C-reactive protein (Appendix B). An ECG showed sinus tachycardia. An urgent abdominal CT revealed mesenteric adenopathy. A SARS-CoV-2 PCR test (GeneXpert®, Cepheid) of nasopharyngeal swab was positive with a cycle threshold (Ct) >30. Lumbar puncture was normal. Blood cultures, stool cultures and urine cultures were negative. Serologies, performed with chemilumi-



**Fig. 1.** Lymph nodes with necrotising lymphadenitis: ischaemic necrosis with necrotising vasculitis (A), periganglionic vessels with red thrombus (B), follicular hyperplasia with immunoblastic reaction (C), plasmacytosis and sinus histiocytosis (D). Presence of occasional microgranulomas (E) (arrow). Positive immunohistochemistry for SARS-CoV-2 (F).

nescence immunoassay, were negative for HIV (IgM + IgG + agp24), syphilis (IgG + IgM), *Toxoplasma*, mumps, rubella, *Coxiella*, *Rickettsia*, *Bartonella* and *Legionella* (IgG and IgM), hepatitis C (IgG) and hepatitis B (negative HBsAg, anti-HBs and anti-HBc), while positive IgG was detected with negative IgM for CMV, EBV, parvovirus and VZV and positive IgG for SARS-CoV-2. A PCR test for *Leishmania* (Werfen) was negative. The autoimmunity study was normal. The patient's condition deteriorated on the ward, with worsening clinical signs and test results (Appendix B), so treatment with piperacillin-tazobactam and doxycycline was started. On the fourth day after admission, she presented shock (BP: 70/40 mmHg; HR: 136 bpm) and severe oliguria, which did not respond to fluid therapy, so a new thoraco-abdominopelvic CT (Appendix B) was performed, which showed generalised adenopathy, especially in the root of the mesentery and RIF, mild splenomegaly, fluid in the pericardial recess, periportal oedema and mild to moderate ascites. She was admitted to the ICU and treated with piperacillin-tazobactam, linezolid, ganciclovir and liposomal amphotericin B, pending microbiological results. Suspecting septic shock of abdominal/gynaecological origin, an exploratory laparotomy was performed, which resulted in no pathological findings, except for mesenteric and mesocolic lymphadenitis. The affected lymph nodes were resected.

The biopsy revealed necrotising lymphadenitis and reactive lymphoid hyperplasia with extensive sinusoidal histiocytosis, with no haemophagocytosis phenomena observed (Fig. 1). A PCR test for SARS-CoV-2 in the lymph node (GeneXpert®, Cepheid) was positive. The patient was started on dexamethasone (20 mg/day), with clinical improvement; the norepinephrine was withdrawn and she was sent back to the ward. There, her vomiting and cytopenia persisted and she required the transfusion of two units of packed red blood cells due to anaemia. A bone marrow biopsy (Appendix B) showed moderate hypocellularity, with a mosaic pattern. An echocardiogram showed mild pericardial effusion and normal systolic and coronary function. Lastly, MIS-A was diagnosed, since it met the criteria for a definitive case.<sup>3</sup> Intravenous immunoglobulin (IVIG) (2 g/kg) was added, with improved clinical signs and test results being observed. The patient was discharged with decreasing

corticosteroids, acetylsalicylic acid (100 mg/day) and prophylactic enoxaparin. Six weeks later, she was asymptomatic and an echocardiogram was normal, so the acetylsalicylic acid was withdrawn.

The patient was initially managed as a case of haemophagocytic lymphohistiocytosis.<sup>4</sup> However, she met criteria for a definitive case (level 1) of MIS-A, according to the *Brighton Collaboration* case definitions of 2021,<sup>3</sup> and her response was very good to treatment with IVIG and corticosteroids. The pathogenesis of MIS-A is unknown. It could be due to an aberrant interferon response that leads to a hyperinflammatory state, with endothelial dysfunction and microangiopathy.<sup>1</sup> Most of the cases described are in young adults from ethnic minorities<sup>5,6</sup> two to five weeks after SARS-CoV-2 infection, with predominantly cardiac and gastrointestinal involvement and a mortality rate of 3.9–11.1%.<sup>2,5,6</sup> Cases associated with vaccination against SARS-CoV-2 have also been described.<sup>7</sup> Treatment is extrapolated from paediatric recommendations<sup>8</sup>; the use of IVIG and corticosteroids<sup>9</sup> is recommended, although a recent article has found no benefit from the combination in children.<sup>10</sup>

In conclusion, MIS-A should be suspected in all adults with a history of COVID-19 in the last 12 weeks who present with fever, inflammatory markers, cardiovascular involvement and extrapulmonary organ involvement, and early treatment with IVIG or corticosteroids should be established.

#### Funding

We confirm that no funding was received from any organisation or institution for the writing of this manuscript.

#### Conflicts of interest

The authors declare that they have no conflicts of interest.

#### Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:<https://doi.org/10.1016/j.eimc.2021.10.009>.

## References

- Kabeerdoss J, Pilania RK, Karkhele R, Kumar TS, Danda D, Singh S. Severe COVID-19, multisystem inflammatory syndrome in children, and Kawasaki disease: immunological mechanisms, clinical manifestations and management. *Rheumatol Int.* 2021;41:19–32. Available from: <https://pubmed.ncbi.nlm.nih.gov/33219837/>. [cited 2021 April 17].
- Bastug A, Aslaner H, Aybar Bilir Y, Kemirtlek N, Gursoy FM, Bastug S, et al. Multiple system inflammatory syndrome associated with SARS-CoV-2 infection in an adult and an adolescent. *Rheumatol Int.* 2021;41. Available from: <https://pubmed.ncbi.nlm.nih.gov/33742229/>. [cited 2021 April 17].
- Vogel TP, Top KA, Karatzios C, Hilmers DC, Tapia LI, Mocerri P, et al. Multisystem inflammatory syndrome in children and adults (MIS-C/A): case definition & guidelines for data collection, analysis, and presentation of immunization safety data. *Vaccine.* 2021.
- La Rosée P, Horne AC, Hines M, Greenwood TVB, Machowicz R, Berliner N, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. *Blood.* 2019;133:2465–77. Available from: <http://ashpublications.org/blood/article-pdf/133/23/2465/1553600/blood894618.pdf>. [cited 2021 April 17].
- Morris SB, Schwartz NG, Patel P, Abbo L, Beauchamps L, Balan S, et al. Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection – United Kingdom and United States, March–August 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69:1450–6. Available from: <https://pubmed.ncbi.nlm.nih.gov/33031361/>. [cited 2021 April 17].
- Davogusto GE, Clark DE, Hardison E, Yanis AH, Lowery BD, Halasa NB, et al. Characteristics associated with multisystem inflammatory syndrome among adults with SARS-CoV-2 infection. *JAMA Network Open.* 2021;4. Available from: <https://pubmed.ncbi.nlm.nih.gov/34009351/>. [cited 2021 July 10].
- Salzman MB, Huang C-W, O'Brien CM, Castillo RD. Multisystem inflammatory syndrome after SARS-CoV-2 infection and COVID-19 vaccination. *Emerg Infect Dis.* 2021;27:1944–8. Available from: <https://pubmed.ncbi.nlm.nih.gov/34034858/>. [cited 2021 July 10].
- García Salido A, Antón J, Marín-Pajares JD, Giralte García G, Gómez-Cortés B, Tagarro A. Grupo de trabajo de la Asociación Española de Pediatría para el síndrome inflamatorio multisistémico pediátrico vinculado a SARS-CoV-2. Consenso nacional sobre diagnóstico, estabilización y tratamiento del síndrome inflamatorio multisistémico pediátrico vinculado a SARS-CoV-2. (*SIM-PedS*). *Anales Pediat.* 2021;94, 116.e1–11.
- Son MBF, Murray N, Friedman K, Young CC, Newhams MM, Feldstein LR, et al. Multisystem inflammatory syndrome in children – initial therapy and outcomes. *N Engl J Med.* 2021;385:23–34. Available from: <https://www.nejm.org/doi/full/10.1056/NEJMoa2102605>. [cited 2021 July 10].
- McArdle AJ, Vito O, Patel H, Seaby EG, Shah P, Wilson C, et al. Treatment of multisystem inflammatory syndrome in children. *N Engl J Med.* 2021;385:11–22. Available from: <https://pubmed.ncbi.nlm.nih.gov/34133854/>. [cited 2021 July 10].

Jara Llenas-García<sup>a,b,\*</sup>, Mari Luz Paredes-Martínez<sup>c</sup>, Pedro Luis Boils-Arroyo<sup>d</sup>, Isabel María Pérez-Gómez<sup>e</sup>

<sup>a</sup> Servicio de Medicina Interna-Infeciosas, Hospital Vega Baja, FISABIO, Orihuela (Alicante), Spain

<sup>b</sup> Departamento de Medicina Clínica, Universidad Miguel Hernández, Elche (Alicante), Spain

<sup>c</sup> Servicio de Radiodiagnóstico, Hospital Vega Baja, FISABIO, Orihuela (Alicante), Spain

<sup>d</sup> Servicio de Anatomía Patológica, Hospital Vega Baja, FISABIO, Orihuela (Alicante), Spain

<sup>e</sup> Unidad de Medicina Intensiva, Hospital Vega Baja, FISABIO, Orihuela (Alicante), Spain

\* Corresponding author.

E-mail address: [jarallenas@gmail.com](mailto:jarallenas@gmail.com) (J. Llenas-García).

<https://doi.org/10.1016/j.eimce.2022.04.006>

2529-993X/ © 2021 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Published by Elsevier España, S.L.U. All rights reserved.

### Rapid diagnosis of pulmonary tuberculosis using Xpert MTB/RIF assay in gastric aspirate samples from adult patients with sputum-absent disease: A first-step alternative to bronchoscopy?



#### Diagnóstico precoz de la tuberculosis pulmonar mediante Xpert MTB/RIF en muestras obtenidas mediante aspirado gástrico en pacientes adultos que no expectoran: ¿una alternativa previa a la broncoscopia?

Sputum-absent pulmonary tuberculosis (PTB) is common in adult patients. It leads to misdiagnoses and delays of PTB and forces to rely on alternative diagnostic approaches such as bronchoscopy (BC). XpertMTB/RIF on gastric aspirate (GA) sampling is an option in this scenario,<sup>1</sup> mainly in the pediatric population,<sup>2</sup> but evidence of its usefulness on the adult population is scarce and no previous work has studied its diagnostic performance compared with a reference standard such as tuberculosis culture (TC) from BC samples. TC from GA samples has been previously compared with TC from BC samples showing a positive culture yield of 21% vs. 34% respectively.<sup>3</sup>

In the present study we compared the diagnostic yield of the Xpert MTB/RIF assay in GA samples with regard to TC obtained through BC in adult patients with suspected PTB and no sputum production. The secondary aim was to compare the diagnostic performance of the Xpert MTB/RIF assay versus that of the TC in the same GA sample. Overall, confirmed PTB diagnosis was made if either Xpert MTB/RIF assay or TC were positive.

We retrospectively reviewed all the GA samples obtained between January 2015 and May 2018 from adult patients with clinical or radiological suspicion of PTB, no sputum production and which fulfilled the inclusion criteria: (a) GA samples were processed for TC and Xpert MTB/RIF; (b) when the GA Xpert MTB/RIF assay was negative a TC was obtained through BC. GA samples were obtained through nasogastric tube in the morning after overnight fasting, and then processed and decontaminated within less than 2 h from sampling.<sup>4</sup> Since no bronchoscopic sampling was performed in patients with a positive Xpert MTB/RIF assay in GA, it was assumed that all GA-positive patients would have been diagnosed with TC obtained through BC.

Forty-three GA samples from 43 patients were reviewed and 31 were finally included in the analysis. The Xpert MTB/RIF was positive in 9 patients (29.0% [9/31]). Eight of them had a positive TC in the same GA sample, whereas the GA culture of the remaining patient was contaminated. Among the 22 patients with negative Xpert MTB/RIF assay in GA (70.9% [22/31]), two (9.1% [2/22]) had a positive TC only in the BC sample and one additional patient (4.5% [1/22]) had a positive TC only in the GA sample. Overall, the diagnosis of PTB was confirmed on the basis of TC performed in GA and/or BC samples in 12 patients (38.7% [12/31] of the overall study cohort).

The sensitivity and specificity of the Xpert MTB/RIF assay in GA samples by using TC in BC samples as reference method were 81.9% (95% CI: 48.2–97.7) and 100.0% (95% CI: 83.2–100), respectively. The NPV was estimated at 90.9% (95% CI: 74.1–97.2) (Table 1). On the other hand, the Xpert MTB/RIF assay exhibited a sensitivity of 88.9% (95% CI: 51.8–99.7) and a specificity of 95.5%